Oct 16, "Being the first LP to launch a vape-ready CBD-rich product for the rapidly growing The first batch of Aurora Cloud cannabis oil cartridges are made with independent laboratory analysis reports on cannabinoid potency. Oct 16, “Being the first LP to launch a vape-ready CBD-rich product for the rapidly growing The first batch of Aurora Cloud cannabis oil cartridges are made with independent laboratory analysis reports on cannabinoid potency. Oct 16, To be the first to bring a legal vape product to market is the sort of . than 30mg of THC, making them the only vape-ready CBD products legally.
Cannabis CBD to Becomes Oil Cartridges Aurora LP Launch First High-Potency Vape-Ready,
We are very proud of this accomplishment by our teams, and will continue to leverage our leadership in executing on our strategy to develop a robust portfolio of high value-add, higher-margin products for all markets and jurisdictions that we participate in. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs.
For more information about Aurora, please visit our investor website: These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither TSX nor its Regulation Services Provider as that term is defined in the policies of Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.
This site uses Akismet to reduce spam. Learn how your comment data is processed. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. The electricity consumed by the facility is supplied through two independent sub-stations, which feed two independent electrical rings.
The rings have interconnects, as well as a back-up independent power generator, to ensure full redundancy. Furthermore, the electrical rings are monitored and controlled by a digitalized management system with switch gear to move power through the facility quickly and efficiently.
The measures described above ensure a very significant reduction in energy use compared to more traditional facilities that yield a similar production output on an annual basis. This license allows Aurora to expand research and product development activities with cannabinoids and their derivatives not covered under the Cannabis Act, as well as import and export cannabis products to and from international markets, subject to applicable regulations.
Aurora is producing unique, integral hard-shell capsules for the medical and adult consumer use markets. The facility is now operating at full capacity, producing at a run rate of 4, kg per annum. The Company utilizes technology it has exclusively licensed from strategic partner Capcium, in which Aurora has a strategic investment. High volume production of softgels at Vie has started, resulting in greater availability of this higher margin product.
The facility is ramping up to its full 8, kg per annum capacity, increasing product availability for the EU markets. The Company has commenced with a 54, square feet expansion of Base One, anticipated to be fully completed towards the end of the first calendar quarter of Pharma-grade processing equipment will be moved into the facility, with completion and full commission anticipated for early This certification will allow MedReleaf Markham to access rapidly growing, higher margin, heavily regulated EU markets.
This license allows MedReleaf Bradford, a , square foot facility which features a high-volume CO2 extraction facility, to significantly increase the production of oils in fiscal MedReleaf Bradford continues to produce oils, a higher-margin product, in anticipation of the receipt of its oils sales license. Two additional grow rooms were recently commissioned with only two grow rooms remaining to be licensed.
Aurora expects to commence erecting the buildings metal frame in the beginning of calendar year Near completion of the piling work is a major milestone as it ensures greater efficiency of construction work during the winter months.
Facility upgrades are continuing, and increased yields and efficiencies are already being realized. The Company is successfully executing on a comprehensive innovation strategy that covers the entire cannabis industry value chain from breeding and genetics, through facility development to medical research product development and post production analytics. Objective of the innovation strategy is to yield industry leading operational efficiencies, as well as the development of a broad portfolio of high-margin, targeted medical and consumer use products.
Aurora has been executing successfully on developing a fully vertically integrated company. To date the Company has completed over 25 transactions acquisitions and strategic investments , covering the entire spectrum of the cannabis industry value chain. Consequently, Aurora has been successful in establishing leadership across its activities and is exceptionally well positioned to capitalize on its early mover advantage globally, across its medical, wellness, and adult consumer use market segments.
The Wagner Dimas technology has now been installed at Aurora, and the large-scale production of pre-rolled product has commenced in order to fulfill orders received from provincial buyers who have begun supplying the Canadian adult-use market.
Cannabis extracts revenue for Q4 and Q1 comprised solely of cannabis oil revenue. Revenue growth compared to the same quarter in the prior year was attributable mainly to higher patient numbers following the acquisition of CanniMed and MedReleaf, increased product availability through scale up of operations from the CanniMed and MedReleaf acquisitions, an increase in the average net selling price of dried cannabis, development of international markets, the commencement of the Canadian adult-use market, and product diversification.
Production costs per gram are expected to decrease significantly once Aurora Sky is fully operational and the efficiencies from automation, scale and yield expertise are realized at all Aurora facilities. The change in gross profit during the period was partially attributable to higher sales of inventory and lower fair value gains on changes in biological assets, which were partially offset by higher gross profits before fair value adjustments. Aurora continues to make significant investments in its infrastructure and skilled talent, scaling the organization to better realize the tremendous opportunities ahead in the global medical cannabis markets and the Canadian adult consumer-use market.
The increase was primarily attributable to the unrealized non-cash gain on derivatives and marketable securities, which was partially offset by increased finance costs, share-based payments, acquisition and project evaluation costs. The Company also has strategic investments in a number of publicly-traded companies. The Company anticipates that it has sufficient liquidity and capital resources to meet all of its currently planned expenditures for at least the next twelve months.
Aurora is exceptionally well-positioned in all of its active markets, including adult consumer-use market, Canadian medical and the international medical markets, with compelling brands, a broad and expanding product portfolio, and strong patient and consumer recognition.
In fiscal , the Company will continue to focus on expanding capacity and sales growth in all its markets, in addition to exploiting further product development and innovation, medical research, continued international expansion and realization of acquisition synergies. Aurora is rapidly accelerating production out of its newly licensed facilities, starting with Aurora Sky, which is expected to ramp to full , kg per annum capacity over the coming months.
Management believes these factors together will deliver high growth and continuously improving margins. Management believes this early mover advantage, coupled with the strength of its growing international management teams, will enable the Company to continue expanding its significant market share in the global medical market. The Company granted a total of , options to purchase common shares of Aurora to Officers of the Company.
Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution. Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost.
Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Q4 and Q1 cannabis revenues were comprised solely of revenues from medical cannabis 2 Represents the gross margin on cannabis sales before fair value adjustments 3 Represents the cash cost of sales and cost to produce per gram sold of dried cannabis produced by Aurora 4 Represents the average net selling price per gram of dried cannabis or per gram of dried cannabis equivalent.
Aurora Cannabis Becomes First LP to Launch Vape-Ready, High-Potency CBD Oil Cartridges
Positions Company to Capture Leadership in High-Growth Medical and Wellness Markets TSX: ACB EDMONTON, Oct. 16, /CNW/ - Aurora Aurora Cannabis Becomes First LP to Launch Vape-Ready, High-Potency CBD Oil Cartridges. Oct 19, Becoming the first Licensed Producer in Canada to launch CBD oils, the “ Being the first LP to launch a vape-ready CBD-rich product for the rapidly to develop a robust portfolio of high value-add, higher-margin products for all The first batch of Aurora Cloud cannabis oil cartridges are made with. Aurora Cannabis Inc. (ACBFF: OTCQX International) | Aurora Cannabis Becomes First LP to Launch Vape-Ready, High-Potency CBD Oil Cartridges.